The causes of premature death in untreated Cushing’s syndrome are vascular disease (myocardial infarction/stroke), uncontrolled diabetes mellitus and complications and infections. Long-term mortality outcome studies on pituitary-dependent Cushing’s disease (CD) are limited to six studies in the English language literature. This paper reviews these studies on CD, other causes of Cushing’s syndrome being excluded, because CD represents 80% of patients with the syndrome. The period covered by these studies (1970–1990) is when transsphenoidal surgery was well established as primary treatment for CD. Two studies were exclusively from surgical centres and are likely biased in favour of surgically resectable adenomas, so this needs to be borne in mind when interpreting their results. The criteria for remission of hypercortisolism and persistent disease were variable. The overall number of patients in each report is small, and the number of deaths even smaller by epidemiological standards giving very wide confidence intervals to the standardised mortality ratios (SMR). Moreover, follow-up time was relatively short (median 10–12 years) for a disease diagnosed in the patients’ late 30s. Notwithstanding the above limitations of retrospective studies, and potential for positive bias, the overall SMR of around 1.5 was not significantly different from the relevant normal population for those patients deemed in remission. However, SMR was significantly worse for those patients with persistent disease. Where it was possible to analyse contributing factors to mortality, the presence of hypertension and diabetes mellitus, in addition to persistence of hypercortisolism, was shown to be significant. It remains possible that an overall SMR in ‘cured’ patients would be significant given a larger cohort, followed for longer, and with more deaths. What is clearly required is a multicentre prospective cohort study with >30 years’ follow-up to answer the question definitively and identify the contributing factors in detail in order to achieve optimum long-term outcome.

Keywords:
Cushing’s disease, Mortality outcomes, Determinants of mortality
1.
Lindholm J, Juul S, Jørgensen JO, et al: Incidence and late prognosis of Cushing’s syndrome: a population based study. JCEM 2001;86:117–123.
2.
Boscaro M, Arnaldi G: Approach to the patient with possible Cushing’s syndrome. JCEM 2009;94:3121–3131.
3.
Plotz D, Knowlton AI, Ragan C: The natural history of Cushing’s disease. Am J Med 1952;13:597–614.
4.
O’Riordain DS, Farley DR, Young WF Jr, et al: Long-term outcome of bilateral adrenalectomy in patients with Cushing’s syndrome. Surgery 1994;116:1088–1093.
5.
Rajasoorya C, Holdaway IM, Wrightson P, et al: Determinant of clinical outcome and survival in acromegaly. Clin Endocrinol 1994;41:95–102.
6.
Melmed S, Colao A, Barkan A, et al: Guidelines for acromegaly management: an update. JCEM 2009;94:1509–1517.
7.
Etxabe J, Vazquez JA: Morbidity and mortality in Cushing’s disease and epidemiological approach. Clin Endocrinol 1994;40:479–484.
8.
Swearingen B, Biller BM, Barker FG 2nd, et al: Long-term mortality after transsphenoidal surgery for Cushing’s disease. Am Int Med 1999;130:821–824.
9.
Hammer GD, Tyrrell JB, Lamborn KR, et al: Transsphenoidal microsurgery for Cushing’s disease: initial outcomes and long-term results. JCEM 2004;89:6348–6357.
10.
Pikkarainen L, Sane T, Reunanen A: The survival and well-being of patients treated for Cushing’s syndrome. J Intern Med 1999;245:463–468.
11.
Dekkers OM, Biermasz NR, Pereira AM, et al: Mortality in patients treated for Cushing’s disease is increased, compared with patients treated for non-functioning pituitary macroadenomas. JCEM 2007;92:976–981.
12.
Colao A, Pivonello R, Spiezia S, et al: Persistence of increased cardiovascular risk in patients with Cushing’s disease after 5 years of successful cure. JCEM 1999;84:2664–2672.
13.
Arnaldi G, Mancini T, Polenta B, et al: Cardiovascular risk in Cushing’s disease. Pituitary 2004;4:253–256.
14.
Tomlinson JW, Holden N, Hills RK, et al: Association between premature mortality and hypopituitarism: West Midlands Prospective Hypopituitary Study group. Lancet 2001;357:425–431.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.